利培酮合并米氮平治疗精神分裂症阴性症状68例临床研究

The clinical research of Risperidone combined Mirtazapine in the treatment of negative symptoms of schizophrenia in 68 patients

目的:探讨利培酮合并米氮平治疗精神分裂症阴性症状的临床疗效及安全性。方法:将136例以阴性症状为主的精神分裂症患者随机分为研究组(利培酮合并米氮平治疗)和对照组(单用利培酮治疗),疗程10周,采用阳性和阴性综合征量表(PANSS)和治疗中需处理的不良反应症状量表(TESS)评定疗效和安全性。结果:治疗后两组PANSS评分均较治疗前有显著降低(P<0.05)。治疗后第4、6、8、10周末,研究组的阴性因子分均显著低于对照组,差异具有显著性(P<0.05或P<0.01)。两组不良反应均为轻至中度。结论:利培酮合并米氮平治疗精神分裂症阴性症状具有起效快、疗效好、不良反应少、患者依从性好的特点。

Objective：To evaluate clinical efficacy and safety of Risperidone combined Mirtazapine in the treatment of negative symptoms of schizophrenia.Methods：136 patients with predominantly negative symptoms of schizophrenia were randomly divided into study group（Risperidone combined Mirtazapine） and the control group（Risperidone alone） with10 weeks＇ treatment.PANSS and TESS assessed the efficacy and safety respectively.Results： After treatment,PANSS scores were significantly lower before treatment（P0.05）.4,6,8,10 week after treatment,the negative factor scores of study group were significantly lower than the control group,the difference was significant（P0.05 or P0.01）.Two groups of adverse events were mild to moderate.Conclusions： Risperidone combined Mirtazapine in the treatment of schizophrenia with negative symptoms of rapid onset,better efficacy,fewer side effects,and good patient compliance.